Reaction
Onycholysis reporting signals
As of the last recalculation, Onycholysis appears in 1,533 FAERS reports alongside 35 co-occurring drug terms. The strongest observed disproportionality signal is DOCETAXEL ANHYDROUS (PRR 32.2).
Important: FAERS is a spontaneous, voluntary, unverified reporting system. PRR and ROR identify reporting patterns for investigation; they are not incidence rates and do not establish causation.
| Drug | Co-reports | PRR | ROR |
|---|---|---|---|
| Docetaxel Anhydrous | 145 | 32.2 | 32.2 |
| Docetaxel | 145 | 32.2 | 32.2 |
| Pertuzumab | 59 | 30.6 | 30.7 |
| Trastuzumab | 136 | 29.4 | 29.5 |
| Ado-Trastuzumab Emtansine | 18 | 29.3 | 29.4 |
| Paclitaxel (Aibumin-Bound) | 152 | 27.8 | 27.8 |
| Lapatinib | 31 | 27.7 | 27.7 |
| Paclitaxel | 169 | 25.9 | 26.0 |
| Capecitabine | 118 | 18.9 | 18.9 |
| Desloratadine | 14 | 17.9 | 17.9 |
| Panitumumab | 19 | 16.7 | 16.7 |
| Cetuximab | 31 | 13.7 | 13.7 |
| Zoledronic Acid | 33 | 11.4 | 11.4 |
| Amitriptyline Hydrochloride | 14 | 10.9 | 10.9 |
| Exemestane | 17 | 10.9 | 10.9 |
| Terbinafine Hydrochloride | 7 | 10.7 | 10.8 |
| Clobetasol Propionate Ointment Usp, 0.05% | 8 | 10.6 | 10.6 |
| Clobetasol Propionate | 8 | 10.6 | 10.6 |
| Filgrastim | 27 | 9.9 | 9.9 |
| Fluorouracil | 48 | 8.7 | 8.7 |
| Fluorouracil Cream, 0.5% | 47 | 8.6 | 8.6 |
| Ixekizumab | 23 | 8.6 | 8.6 |
| Secukinumab | 85 | 7.5 | 7.5 |
| Carboplatin | 59 | 6.5 | 6.5 |
| Bevacizumab | 57 | 6.5 | 6.5 |
| Oxaliplatin | 34 | 6.3 | 6.3 |
| Abemaciclib | 7 | 4.8 | 4.8 |
| Bosutinib | 3 | 4.5 | 4.5 |
| Palbociclib | 29 | 4.2 | 4.2 |
| Osimertinib | 9 | 3.8 | 3.8 |
| Bimekizumab | 5 | 3.2 | 3.2 |
| Enzalutamide | 13 | 3.0 | 3.0 |
| Relugolix | 4 | 2.3 | 2.3 |
| Apremilast | 21 | 2.0 | 2.0 |
| Salicylic Acid | 5 | 1.3 | 1.3 |